CTOs on the Move


 
As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.draper.com
  • 555 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.258.1000

Executives

Name Title Contact Details
Jennifer Doherty
Vice President, Chief Security Officer and Chief Information Officer Profile
Jonathan Cos
Associate Director of Information Security Profile
Kevin Burns
Chief Information Security Officer Profile

Similar Companies

AltheaDx

AltheaDx, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. AltheaDx, Inc. is based in San Diego, CA. You can find more information on AltheaDx, Inc. at www.altheadx.com

Nanogen, Inc.

Nanogen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Akriveia Therapeutics

`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.

ProteinOne

ProteinOne is a Derwood, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.